Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Misaq Pharmaceuticals Pvt Ltd.

Private pharmaceutical manufacturer · Pakistan

Pakistan pharmaceutical manufacturer holding DRAP Drug Manufacturing Licence 000985 and marketing registered prescription products.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date1 Jul 2025Newest effective date among published current price records
Corporate profile evidence1 sourceCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Misaq Pharmaceuticals Pvt. Ltd.
Company type
Private pharmaceutical manufacturer
Corporate source details checked
16 Aug 2026
Corporate profile completeness
38%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000985 Misaq Pharmaceuticals (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000985 32 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Exact site not yet sourced

No exact premises location is published without a defensible source.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx32public portfolio records represented
REG30unique registrations represented
IDX32indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR32current validated price records
G15generic molecules in indexed catalogue
DF6dosage-form groups
TA3therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage100%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMisaq Pharmaceuticals Pvt Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/misaq-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026Anti-infectives24 · 75%Vitamins, minerals & nutrition4 · 13%Gastrointestinal & hepatology4 · 13%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMisaq Pharmaceuticals Pvt Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/misaq-pharmaceuticals-pvt-ltdGenerated 23 Sep 202632presentationsInjection12 · 38%Tablet7 · 22%Capsule5 · 16%Suspension4 · 13%Solution3 · 9%Cream1 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMisaq Pharmaceuticals Pvt Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/misaq-pharmaceuticals-pvt-ltdGenerated 23 Sep 202630comparable productsBelow peer median3 · 10%Near peer median18 · 60%Above peer median9 · 30%Company median price position+2.9%Lowest-price equivalents1Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMisaq Pharmaceuticals Pvt Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/misaq-pharmaceuticals-pvt-ltdGenerated 23 Sep 2026M/s. Genix Pharma (Pvt) Ltd.14 shared93% overlapPharmasol (Pvt) Ltd.13 shared87% overlapBio-Labs(Pvt) Ltd13 shared87% overlapNeutro Pharma (Pvt.) Ltd.,13 shared87% overlapMaxitech Pharma (Pvt) Ltd.13 shared87% overlapWinlet Pharmaceuticals (Pvt) Ltd.13 shared87% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives24 products · 75%
Vitamins, minerals & nutrition4 products · 13%
Gastrointestinal & hepatology4 products · 13%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins8 products · 25%
Fluoroquinolone antibacterials4 products · 13%
Antifungals3 products · 9%
Antiseptics & disinfectants3 products · 9%
Macrolide antibacterials3 products · 9%
Vitamin K / haemostatic agents2 products · 6%
Carbapenem antibacterials2 products · 6%
Vitamins / minerals / hematinics2 products · 6%
Formulation footprint

Dosage forms

Injection12 products
Tablet7 products
Capsule5 products
Suspension4 products
Solution3 products
Cream1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 LezoneCeftriaxone 5presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 Misodine surgical scrubPovidone-iodine 3presentations 10 %, 7.5 % · Solution #3 BexoCefixime 2presentations 100 mg/5 mL, 400 mg · Suspension, Capsule #4 K-SaqPhytomenadione 2presentations 10 mg, 2 mg · Injection #5 LevosaqLevofloxacin 2presentations 250 mg, 500 mg · Tablet #6 MerosaqMeropenem 2presentations 1 g, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median310% of comparable products
Near market median18within ±5% of median
Above market median930% of comparable products
Lowest-price equivalents1ties included
Company median price position +2.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Flusaq 150 mgFluconazole · Capsule · 1’s PKR 182.92/capsule-30.7% vs market median Mira-D 5 mgCholecalciferol · Injection · 5'S PKR 183.82/vial/unit-5.4% vs market median Bexo 400 mgCefixime · Capsule · 5's PKR 107.32/capsule-4.9% vs market median Bexo D/S 200 mg/5 mLCefixime · Dry suspension · 30ml PKR 12.22/mL-4.9% vs market median Misafin w/w 1 %Terbinafine · Cream · 10gm PKR 28.06/g-4.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 14shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 13shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 13shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 13shared generics Maxitech Pharma (Pvt) Ltd.117 products · 45 generics 13shared generics Winlet Pharmaceuticals (Pvt) Ltd.117 products · 45 generics 13shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers30Distinct registrations among indexed, published, presentation-validated products only
Verified price observations32
Products with a verified price32
Products with multiple price observations0
Source records with multiple versions32
Latest portfolio source check9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

30 unique registration(s) · 32 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Bexo Cefixime 100 mg/5 mL Dry suspension 30ml 129871 PKR 299.46 PKR 9.98/mL Near median
Bexo Cefixime 400 mg Capsule 5's 131475 PKR 536.60 PKR 107.32/capsule Near median
Bexo D/S Cefixime 200 mg/5 mL Dry suspension 30ml 129872 PKR 366.46 PKR 12.22/mL Near median
Flusaq Fluconazole 150 mg Capsule 1’s 129964 PKR 182.92 PKR 182.92/capsule 31% below median
Itrosaq Itraconazole 100 mg Capsule 4’s 129962 PKR 618.16 PKR 154.54/capsule 7% above median
K-Saq Phytomenadione 10 mg Injection 1 'S 124575 PKR 264.56 PKR 264.56/vial/unit No comparator
K-Saq Phytomenadione 2 mg Injection 1'S 124576 PKR 157.45 PKR 157.45/vial/unit No comparator
Levosaq Levofloxacin 250 mg Tablet 10'S 124573 PKR 492.02 PKR 49.20/tablet Near median
Levosaq Levofloxacin 500 mg Tablet 10'S 124574 PKR 818.72 PKR 81.87/tablet Near median
Lezone Ceftriaxone 2 g Injection 01 Vial 131437 PKR 885.66 PKR 885.66/vial/unit 10% above median
Lezone Ceftriaxone 250 mg Injection 01 Vial 131499 PKR 198.78 PKR 198.78/vial/unit Near median
Lezone Ceftriaxone 250 mg Injection 01 Vial 131500 PKR 198.78 PKR 198.78/vial/unit Near median
Lezone Ceftriaxone 500 mg Injection 01 Vial 131501 PKR 334.58 PKR 334.58/vial/unit Near median
Lezone Ceftriaxone 1 g Injection 01 Vial 131502 PKR 631.77 PKR 631.77/vial/unit 5% above median
Linerex D/S Linezolid 100 mg/5 mL Dry suspension 60ml 129862 PKR 688.85 PKR 11.48/mL 7% above median
Merosaq Meropenem 500 mg Injection 01 Vial 129868 PKR 2,105.91 PKR 2,105.91/vial/unit Near median
Merosaq Meropenem 1 g Injection 01 Vial 129869 PKR 3,936.28 PKR 3,936.28/vial/unit Near median
Micip Ciprofloxacin 500 mg Tablet 10'S 124572 PKR 423.14 PKR 42.31/tablet Near median
Micip Ciprofloxacin 250 mg Tablet 1x10’s 129963 PKR 255.86 PKR 25.59/tablet Near median
Mira-D Cholecalciferol 5 mg Injection 5'S 124577 PKR 919.09 PKR 183.82/vial/unit 5% below median
Mira-D Cholecalciferol 5 mg Injection 1 'S 124577 PKR 216.49 PKR 216.49/vial/unit 12% above median
Misafin w/w Terbinafine 1 % Cream 10gm 129960 PKR 280.56 PKR 28.06/g Near median
Misodine surgical scrub Povidone-iodine 7.5 % Surgical scrub solution 60ml 121477 PKR 156.71 PKR 2.61/mL 44% above median
Misodine surgical scrub Povidone-iodine 10 % Surgical scrub solution 450ml 121478 PKR 792.38 PKR 1.76/mL 30% below median
Misodine surgical scrub Povidone-iodine 10 % Surgical scrub solution 60ml 121478 PKR 150.09 PKR 2.50/mL 42% above median
Mizith Azithromycin 250 mg Tablet 6's 129542 PKR 299.31 PKR 49.89/tablet 6% above median
Mizith Azithromycin 500 mg Tablet 6's 129543 PKR 548.73 PKR 91.46/tablet 8% above median
Mizith D/S Azithromycin 200 mg/5 mL Dry suspension 15mL 129541 PKR 329.24 PKR 21.95/mL Near median
Omesaq Omeprazole 40 mg Capsule 2x7’s 129544 PKR 492.03 PKR 35.15/capsule Near median
Omesaq Omeprazole 20 mg Capsule 2x7’s 129545 PKR 283.41 PKR 20.24/capsule Near median
Ondron Ondansetron 8 mg/4 mL Injection 5's Ampoules 123897 PKR 4,913.56 PKR 982.71/vial/unit Near median
Ondron Ondansetron 8 mg Tablet 10's 129961 PKR 1,692.60 PKR 169.26/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Misaq Pharmaceuticals Pvt Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/misaq-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.